A merger between US-based healthcare conglomerate Baxter and Sweden-based medical technologies company Gambro will be cleared by the European Commission, say reports. The agreement, signed at $4 billion, was modified when Baxter agreed to divest part of the company worth about one-fifth of its annual turnover, said two unnamed sources. Clearance from the European Commission would make the company the second-largest dialysis equipment manufacturer; reports say the global market is set to grow as obesity and diabetes rates climb. The two companies announced the deal last December.
Featured News
Trump Administration Defends Pentagon Blacklisting of AI Firm Anthropic in Court Filing
Mar 18, 2026 by
CPI
BMG Sues Anthropic Over Alleged Use of Song Lyrics in AI Training
Mar 18, 2026 by
CPI
Google Proposes New Search Controls Amid UK Competition Scrutiny
Mar 18, 2026 by
CPI
US Appeals Court Revives Whistleblower Case Against Major Drugmakers Over Pricing Program
Mar 18, 2026 by
CPI
Possible Compromise Emerging on Stablecoin Yield Payments in Senate Market-Structure Bill
Mar 18, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Behavioral Economics
Feb 22, 2026 by
CPI
Behavioral Antitrust in 2026
Feb 22, 2026 by
Maurice Stucke
Behavioral Economics in Competition Policy: Going Beyond Inertia and Framing Effects
Feb 22, 2026 by
Annemieke Tuinstra & Richard May
Agreeing to Disagree in Antitrust
Feb 22, 2026 by
Jorge Padilla
Recognizing What’s Around the Corner: Merger Control, Capabilities, and the New Nature of Potential Competition
Feb 22, 2026 by
Magdalena Kuyterink & David J. Teece